Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11383281 | 1.00 | ALOX15 (0.48) | ALOX15TDP1ALDH1A1TYMSCA12 | |
| SCHEMBL734024 | 0.83 | ALOX15 (0.39) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL3993249 | 0.81 | TDP1 (0.59) | ALOX15TDP1ALDH1A1TYMSCA12 | |
| SCHEMBL30988394 | 0.76 | ALOX15 (0.37) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL19733214 | 0.76 | ALOX15 (0.37) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL2207735 | 0.74 | ALOX15 (0.52) | ALOX15TDP1ALDH1A1TYMSCA12 | |
| SCHEMBL4960375 | 0.71 | ALOX15 (0.43) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL19733211 | 0.71 | ALOX15 (0.37) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL30988393 | 0.71 | ALOX15 (0.37) | ALOX15TDP1ALDH1A1TYMS | |
| SCHEMBL1298310 | 0.71 | ALOX15 (0.48) | ALOX15TDP1ALDH1A1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026090380-A1 | BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115329-A1 | BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250059237-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059237-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM | HDGF, IAPP, QRFPR | ALOX15 2301/4885TDP1 3211/4885ALDH1A1 4431/4885 |
| US-20260115329-A1 | BIORESORBABLE CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS | RAD54L, EGFR, ARG1 | ALOX15 2982/4885TDP1 1151/4885ALDH1A1 334/4885 |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | IAPP, IGFBP6, NPPA | ALOX15 4174/4885TDP1 2325/4885ALDH1A1 4769/4885 |
| US-20260144748-A1 | POLYOL-BASED MULTI-FUNCTIONAL COMPOUNDS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | CD44, PAM, PLOD3 | ALOX15 1626/4885TDP1 3513/4885ALDH1A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.